Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132535 | 1.00 | HCAR2 (0.52) | HCAR2NFE2L2KEAP1TTRAPP | |
| Hydrochloric Acid SCHEMBL2134245 | 0.98 | HCAR2 (0.50) | HCAR2NFE2L2KEAP1TTRAPP | |
| Hydrochloric Acid SCHEMBL2134248 | 0.98 | HCAR2 (0.50) | HCAR2NFE2L2KEAP1TTRAPP | |
| SCHEMBL2607970 | 0.88 | HCAR2 (0.44) | HCAR2NFE2L2KEAP1TTRAPP | |
| SCHEMBL30300922 | 0.85 | HCAR2 (0.46) | HCAR2NFE2L2KEAP1TTRAPP | |
| Hydrochloric Acid SCHEMBL2131093 | 0.84 | HCAR2 (0.44) | HCAR2NFE2L2KEAP1TTRAPP | |
| SCHEMBL30154155 | 0.83 | HCAR2 (0.48) | HCAR2NFE2L2KEAP1TTRAPP | |
| SCHEMBL10044352 | 0.80 | HCAR2 (0.30) | HCAR2 | |
| SCHEMBL938137 | 0.79 | HCAR2 (0.44) | HCAR2NFE2L2KEAP1TTRAPP | |
| SCHEMBL663907 | 0.78 | HCAR2 (0.52) | HCAR2TTRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105968103-A | Synthesis method of anti-tumor medicine afatinib | 山东罗欣药业集团恒欣药业有限公司 | 2016-09-28 | — | — | CN | claimed |
| CN-100415753-C | 4-dimethylamino crotonic acid and its derivatives and their preparation method | WYETH CORP (US) | 2008-09-03 | — | — | CN | claimed |
| CN-1803806-A | Anti-tumor combination drug | WYETH CORP (US) | 2006-07-19 | — | — | CN | claimed |
| CN-118561729-A | Synthetic method and application of nitro cyclic compound | 江南大学 | 2024-08-30 | — | — | CN | disclosed |
| EP-3733663-B1 | 1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS IRREVERSIBLE INHIBITORS OF PAN-HER TYROSINE KINASE FOR THE TREATMENT OF CANCER | CHENGDU JINRUI FOUND BIOTECH CO LTD (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-20220177473-A1 | AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | SHENZHEN FORWARD PHARMACEUTICALS CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20210078958-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2021-03-18 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| EP-1585479-A2 | SYNTHESIS OF 4AMINO-2-BUTENOYL CHLORIDES AND THEIR USE IN THE PREPARATION OF 3-CYANO QUINOLINES | Wyeth (US) | 2005-10-19 | — | — | EP | disclosed |
| CN-1538842-A | Anti-tumor combination drug | — | 2004-10-20 | — | — | CN | disclosed |
| US-20040162442-A1 | Synthesis of 4-(amino)-2-butenoyl chlorides and their use in the preparation of 3-cyano quinolines | WYETH (US) | 2004-08-19 | — | — | US | disclosed |
| WO-2004066919-A2 | SYNTHESIS OF 4AMINO-2-BUTENOYL CHLORIDES AND THEIR USE IN THE PREPARATION OF 3-CYANO QUINOLINES | WYETH (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1414438-A1 | ANTINEOPLASTIC COMBINATIONS | Wyeth (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6617333-B2 | Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methyl propionic acid (CCI-779) and 4-dimethylamino-but-2-enoic acid(4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinol in-6-yl)amide (EKB-569); synergistic; antitumor agents | WYETH | 2003-09-09 | — | — | US | disclosed |
| WO-2003020266-A1 | ANTINEOPLASTIC COMBINATIONS | WYETH (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020266-A1 | ANTINEOPLASTIC COMBINATIONS | WYETH (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20030050222-A1 | Antineoplastic combinations | WYETH | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | HCAR2 1414/4885NFE2L2 527/4885KEAP1 309/4885 |
| US-20030050222-A1 | Antineoplastic combinations | MCL1, BCL9, ERAL1 | HCAR2 2248/4885NFE2L2 921/4885KEAP1 566/4885 |
| US-20220177473-A1 | AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | ERBB4, EGFR, ERBB2 | HCAR2 207/4885NFE2L2 453/4885KEAP1 2290/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | HCAR2 790/4885NFE2L2 155/4885KEAP1 225/4885 |
| US-20210078958-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | ABL1, ERBB2, FLT3 | HCAR2 1131/4885NFE2L2 744/4885KEAP1 278/4885 |
| US-20040162442-A1 | Synthesis of 4-(amino)-2-butenoyl chlorides and their use in the preparation of 3-cyano quinolines | HBS1L, ATXN2L, ASNS | HCAR2 2952/4885NFE2L2 1233/4885KEAP1 1540/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | HCAR2 790/4885NFE2L2 155/4885KEAP1 225/4885 |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | WEE1, WEE2, EGFR | HCAR2 3127/4885NFE2L2 1772/4885KEAP1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.